Tom 5, Nr 2 (2020)
Artykuł przeglądowy
Opublikowany online: 2020-09-10
Wyświetlenia strony 712
Wyświetlenia/pobrania artykułu 210
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Zastosowanie dootrzewnowej chemioterapii w hipertermii (HIPEC) w praktyce klinicznej

Szymon Piątek1, Ksawery Goławski2, Katarzyna Rylewicz2, Mariusz Bidziński1
Ginekologia i Perinatologia Praktyczna 2020;5(2):56-62.

Streszczenie

Hipertermia wywiera cytotoksyczny wpływ na komórki nowotworowe. Chemioterapia dootrzewnowa umożliwia
dostarczenie cytostatyku w bezpośrednią okolicę guza. Jednoczasowe zastosowanie tych metod stwarza szansę
na poprawę wyników leczenia nowotworów przebiegających z rozsiewem wewnątrzotrzewnowym, w tym raka jajnika.
Dokonano przeglądu literatury w zakresie dootrzewnowej chemioterapii w hipertermii (HIPEC, hyperthermic
intraperitoneal chemotherapy) z uwzględnieniem różnych sposobów jej zastosowania, najczęściej stosowanych
cytostatyków oraz powikłań.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980; 40(2): 256–260.
  2. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21(20): 3737–3743.
  3. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978; 62(1): 1–11.
  4. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996; 82: 53–63.
  5. González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010; 2(2): 68–75.
  6. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008; 15(9): 2426–2432.
  7. Overgaard, J. Effect of Hyperthermia on Malignant Cells in Vivo, Cancer. 1977; 39: 2637–46.
  8. de Bree E, Romanos J, Tsiftsis DD. Hyperthermia in anticancer treatment. Eur J Surg Oncol. 2002; 28(1): 95.
  9. Panteix G, Guillaumont M, Cherpin L, et al. Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology. 1993; 50(5): 366–370.
  10. Jacquet P, Averbach A, Stuart OA, et al. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998; 41(2): 147–154.
  11. Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg. 2012; 256(6): 1084–1088.
  12. Ning S, Macleod K, Abra RM, et al. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. Int J Radiat Oncol Biol Phys. 1994; 29(4): 827–834.
  13. Bree Ede, Michelakis D, Stamatiou D, et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura and Peritoneum. 2017; 2(2).
  14. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999; 15(2): 79–107.
  15. Rutkowski P, Śpiewankiewicz B, Herman K, et al. Zasady stosowania dootrzewnowej chemioterapii w hipertermii (HIPEC) w leczeniu nowotworów złośliwych powierzchni otrzewnej w połączeniu z zabiegami cytoredukcyjnymi: zalecenia krajowe. Nowotwory. Journal of Oncology. 2015; 64(6): 518–524.
  16. Brücher BL, Piso P, Verwaal V, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest. 2012; 30(3): 209–224.
  17. Parson EN, Lentz S, Russell G, et al. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011; 202(4): 481–486.
  18. Hyperthermic Intraperitoneal Chemotherapy. Definitions. 2020.
  19. Hotouras A, Desai D, Bhan C, et al. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review. Int J Gynecol Cancer. 2016; 26(4): 661–670.
  20. Baratti D, Kusamura S, Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol. 2008; 98(4): 258–262.
  21. Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008; 98(4): 253–257.
  22. National Cancer Institute (NCI)/National Institute of Health (NIH). Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. . https://webapps.ctep.nci.nih.gov/webobjs/ ctc/webhelp/welcome_to_ctcae.htm (20.01.2020).
  23. Deraco M, Virzì S, Iusco DR, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012; 119(7): 800–809.
  24. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999; 6(8): 790–796.
  25. Argenta PA, Sueblinvong T, Geller MA, et al. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol. 2013; 129(1): 81–85.
  26. Mizumoto A, Canbay E, Hirano M, et al. Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy at a Single Institution in Japan. Gastroenterology Research and Practice. 2012; 2012: 1–5.
  27. Cardi M, Sibio S, Marzo FDi, et al. Prognostic Factors Influencing Infectious Complications after Cytoreductive Surgery and HIPEC: Results from a Tertiary Referral Center. Gastroenterology Research and Practice. 2019; 2019: 1–8.
  28. Canda AE, Sokmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20(4): 1082–1087.
  29. Baratti D, Kusamura S, Laterza B, et al. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol. 2010; 2(1): 36–43.
  30. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009; 249(6): 900–907.
  31. Smeenk RM, Verwaal VJ, Zoetmulder FAN. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007; 94(11): 1408–1414.
  32. Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg. 2012; 255(2): 348–356.
  33. Chua TC, Saxena A, Schellekens JF, et al. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010; 251(1): 101–106.
  34. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003; 10(8): 863–869.
  35. Saxena A, Yan TD, Chua TC, et al. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010; 17(5): 1291–1301.
  36. Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014; 40(12): 1605–1613.
  37. Shan LL, Saxena A, Shan BL, et al. Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis. Surg Oncol. 2014; 23(4): 199–210.
  38. Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012; 127(3): 502–505.
  39. Muñoz-Casares F, Rufián S, Rubio M, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clinical and Translational Oncology. 2009; 11(11): 753–759.
  40. Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Ann Surg Oncol. : 2014.
  41. Safra T, Grisaru D, Inbar M, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014; 110(6): 661–665.
  42. Le Brun JF, Campion L, Berton-Rigaud D, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014; 21(11): 3621–3627.
  43. Driel Wv, Koole S, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. New England Journal of Medicine. 2018; 378(3): 230–240.
  44. Lim M, Chang SJ, Yoo H, et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. Journal of Clinical Oncology. 2017; 35(15_suppl): 5520–5520.
  45. Colombo N, Sessa C, Bois Adu, et al. ESMO–ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019 [Epub ahead of print].
  46. Koole S, Stein Rv, Sikorska K, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. International Journal of Gynecologic Cancer. 2020; 30(6): 888–892.



Ginekologia i Perinatologia Praktyczna